Effects of Long-term Antiepileptic Therapy on Carotid Artery Intima- Media Thickness

Vipul U Kolekar1, Seema P Sindgikar1, Raghuraj Uppoor2

  • 1Department of Paediatrics, K.S. Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, Karnataka, India.

Insights

Children on long-term antiepileptic drugs (AEDs) like valproate, phenytoin, and levetiracetam show increased carotid artery intima-media thickness (CIMT). This suggests potential atherosclerotic changes, necessitating close monitoring for cardiovascular risks.

Area of Science:

  • Pediatrics
  • Neurology
  • Cardiology

Background:

  • Common first-line antiepileptic drugs (AEDs) in children include valproate, phenytoin, and levetiracetam.
  • These AEDs are associated with side effects such as obesity, atherosclerosis, and metabolic syndrome.
  • Long-term AED therapy in children warrants investigation into potential cardiovascular impacts.

Purpose of the Study:

  • To evaluate changes in carotid artery intima-media thickness (CIMT) in epileptic children on long-term AED monotherapy.
  • To correlate CIMT changes with lipid profiles in these pediatric patients.
  • To assess the early atherosclerotic burden associated with common AEDs.

Main Methods:

  • A case-control study involving 84 children (1-18 years) on valproate, phenytoin, or levetiracetam monotherapy for ≥6 months.
  • Carotid artery intima-media thickness (CIMT) measured using B-mode ultrasonography.
  • Lipid profiles analyzed, with statistical analysis using ANOVA and Pearson correlation.

Main Results:

  • No significant difference in Body Mass Index (BMI) between epileptic children and controls.
  • Significantly higher mean CIMT values observed in children on valproate, phenytoin, and levetiracetam compared to controls.
  • Significant correlations found between CIMT and total cholesterol, triglycerides, LDL, and VLDL levels.

Conclusions:

  • Long-term monotherapy with valproate, phenytoin, and levetiracetam is associated with significantly abnormal CIMT in children.
  • Elevated CIMT suggests potential atherosclerotic changes in children on these AEDs.
  • Close follow-up is recommended to mitigate cardiovascular and cerebrovascular risks in these patients.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
61
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
78
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
508
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
46
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
152